Henry Schein Stock Forecast, Price & News

+0.27 (+0.38 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $71.17
50-Day Range
MA: $66.71
52-Week Range
Now: $71.17
Volume732,400 shs
Average Volume1.03 million shs
Market Capitalization$10.13 billion
P/E Ratio17.53
Dividend YieldN/A
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial services on a non-recourse basis, e-services practice, technology, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.
Henry Schein logo

Industry, Sector and Symbol

Industry Medical & hospital equipment
Sub-IndustryHealth Care Distributors
Current SymbolNASDAQ:HSIC
Phone(631) 843-5500
Year Founded1932



Sales & Book Value

Annual Sales$9.99 billion
Cash Flow$4.65 per share
Book Value$24.74 per share


Net Income$694.73 million


Market Cap$10.13 billion
Next Earnings Date5/4/2021 (Estimated)


Henry Schein Reaches Analyst Target Price
April 16, 2021 |
Is HSIC Stock A Buy or Sell?
April 8, 2021 |
Henry Schein Enters Oversold Territory (HSIC)
February 25, 2021 |
Henry Schein's Post-Earnings Blues Not Justified
February 24, 2021 |
See More Headlines


Overall MarketRank

1.72 out of 5 stars

Medical Sector

224th out of 2,024 stocks

Medical & Hospital Equipment Industry

2nd out of 7 stocks

Analyst Opinion: 1.2Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 3.1 5 -4 -3 -2 -1 -
+0.27 (+0.38 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HSIC News and Ratings via Email

Sign-up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

Is Henry Schein a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Henry Schein stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HSIC, but not buy additional shares or sell existing shares.
View analyst ratings for Henry Schein
or view top-rated stocks.

What stocks does MarketBeat like better than Henry Schein?

Wall Street analysts have given Henry Schein a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Henry Schein wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Henry Schein's next earnings date?

Henry Schein is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Henry Schein

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) issued its quarterly earnings data on Tuesday, February, 16th. The company reported $1.00 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.99 by $0.01. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $2.86 billion. Henry Schein had a trailing twelve-month return on equity of 11.60% and a net margin of 6.14%. During the same quarter last year, the company earned $0.97 EPS.
View Henry Schein's earnings history

How has Henry Schein's stock price been impacted by Coronavirus (COVID-19)?

Henry Schein's stock was trading at $57.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HSIC stock has increased by 23.4% and is now trading at $71.17.
View which stocks have been most impacted by COVID-19

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Henry Schein's stock split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein announced that its Board of Directors has approved a stock repurchase plan on Thursday, October 31st 2019, which authorizes the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 4.3% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board believes its stock is undervalued.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 17th. The company provided EPS guidance of 3.51 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.80.

What price target have analysts set for HSIC?

6 brokerages have issued 1-year price objectives for Henry Schein's stock. Their forecasts range from $50.00 to $83.00. On average, they expect Henry Schein's stock price to reach $68.50 in the next twelve months. This suggests that the stock has a possible downside of 3.8%.
View analysts' price targets for Henry Schein
or view top-rated stocks among Wall Street analysts.

Who are Henry Schein's key executives?

Henry Schein's management team includes the following people:
  • Stanley M. Bergman, Chairman & Chief Executive Officer (LinkedIn Profile)
  • James P. Breslawski, Vice Chairman & President
  • Steven Paladino, Chief Financial Officer, Director & Executive VP
  • Christopher Pendergast, Chief Technology Officer & Senior Vice President (LinkedIn Profile)
  • Gerald A. Benjamin, Director, Chief Administrative Officer & EVP (LinkedIn Profile)

What is Stanley M. Bergman's approval rating as Henry Schein's CEO?

451 employees have rated Henry Schein CEO Stanley M. Bergman on Stanley M. Bergman has an approval rating of 94% among Henry Schein's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Henry Schein's key competitors?

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by a variety of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.42%), Wedge Capital Management L L P NC (0.32%), State of Alaska Department of Revenue (0.07%), HGK Asset Management Inc. (0.05%), Retirement Systems of Alabama (0.04%) and Royal London Asset Management Ltd. (0.04%). Company insiders that own Henry Schein stock include Deborah Derby, E Dianne Rekow, Gerald A Benjamin, James P Breslawski, Michael S Ettinger, Paul Brons, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends for Henry Schein

Which major investors are selling Henry Schein stock?

HSIC stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Retirement Systems of Alabama, M&R Capital Management Inc., Pacer Advisors Inc., Neville Rodie & Shaw Inc., and Crossmark Global Holdings Inc.. Company insiders that have sold Henry Schein company stock in the last year include Gerald A Benjamin, and Walter Siegel.
View insider buying and selling activity for Henry Schein
or view top insider-selling stocks.

Which major investors are buying Henry Schein stock?

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., HGK Asset Management Inc., Wedge Capital Management L L P NC, Centric Wealth Management, Everence Capital Management Inc., Pensionfund DSM Netherlands, DnB Asset Management AS, and First Hawaiian Bank.
View insider buying and selling activity for Henry Schein
or or view top insider-buying stocks.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $71.17.

How much money does Henry Schein make?

Henry Schein has a market capitalization of $10.13 billion and generates $9.99 billion in revenue each year. The company earns $694.73 million in net income (profit) each year or $3.51 on an earnings per share basis.

How many employees does Henry Schein have?

Henry Schein employs 19,000 workers across the globe.

Does Henry Schein have any subsidiaries?

The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., General Injectables & Vaccines Inc., HS Brand Management Inc., HS TM Holdings LLC, Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, MEDIVET, Maddox Practice Group, Maravet, Marrodent, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp, Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, and scil animal care.

When was Henry Schein founded?

Henry Schein was founded in 1932.

What is Henry Schein's official website?

The official website for Henry Schein is

Where are Henry Schein's headquarters?

Henry Schein is headquartered at 135 DURYEA RD, MELVILLE NY, 11747.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at (631) 843-5500 or via email at [email protected]

This page was last updated on 4/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.